Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed Mourning Day 01-08 16:00:00 EST

240.55

+4.60

+1.95%

盘后240.55

+0.000.00%

17:52 EST

High240.65	Low234.11	Vol653.99K
Open236.34	D1 Closing235.95	Amplitude2.77%
Mkt Cap31.03B	Tradable Cap30.89B	Total Shares128.98M
T/O156.36M	T/O Rate0.51%	Tradable Shares128.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":240.55,"timestamp":1736370000000,"preClose":235.95,"halted":0,"volume":653987,"hourTrading":{"tag":"盘后","latestPrice":240.55,"preClose":240.55,"latestTime":"17:52 EST","volume":95206,"amount":22901819.25,"timestamp":1736376748467},"delay":0,"floatShares":128427730,"shares":128980917,"eps":-2.620895,"marketStatus":"Closed Mourning Day","change":4.6,"latestTime":"01-08 16:00:00 EST","open":236.34,"high":240.65,"low":234.106,"amount":156356362.97712,"amplitude":0.027735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.620895,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":235.95,"preHourTrading":{"tag":"盘前","latestPrice":234.9,"preClose":235.95,"latestTime":"09:25 EST","volume":11030,"amount":2602518.3524,"timestamp":1736346304238},"postHourTrading":{"tag":"盘后","latestPrice":240.55,"preClose":240.55,"latestTime":"17:52 EST","volume":95206,"amount":22901819.25,"timestamp":1736376748467},"volumeRatio":1.3828848737200456,"impliedVol":0.4254,"impliedVolPercentile":0.5437},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2502770446","title":"Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2502770446","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502770446?lang=en_us&edition=fundamental","pubTime":"2025-01-09 00:58","pubTimestamp":1736355480,"startTime":"0","endTime":"0","summary":"Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer.A hot stock during the pandemic era, when its shares climbed more than 500% between the start of 2020 to early 2021, Vir's gains have since evaporated.The new data comes six months after Vir announced a dramatic change in strategy. Once among the vanishingly few biotechs focused exclusively on infectious disease, Vir has pivoted to cancer, among the most crowded areas for biotech drug development.Wednesday brought the first major update from the company since the August pivot, and the news was good.Vir said that two early-stage drugs, VIR-5818 and VIR-5500, showed \"compelling early clinical response signals\" in an early trial in patients with various solid tumor cancers.Both drugs are based on a technology that Vir has licensed from Sanofi called PRO-XTEN, which helps guide and disguise a type of immunotherapy c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","FORD","PFE","BK4548","BK4588","VIR","BK4539","BK4532","LU1829250122.USD","GSK.UK","BK4568","BK4139","BK4007","ALNY","BK4202","GSK","JANX","BK4585"],"gpt_icon":1},{"id":"2501809167","title":"Alnylam Pharmaceuticals Is Maintained at Outperform by Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2501809167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501809167?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:29","pubTimestamp":1736270940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2025 12:29 ET (17:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2501256361","title":"Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501256361","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501256361?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., January 06, 2025----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT  at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-webcast-presentation-43rd-annual-130000133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","LU0314104364.USD","LU0158827948.USD","BK4548","LU0225283273.USD","LU1989772840.SGD","LU2023251221.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","BK4585","BK4127","BK4516","LU0158827781.USD","LU0267386448.USD","LU1989772923.USD","LU1720051017.SGD","LU0006306889.USD","LU2347655156.SGD","LU1363072403.SGD","ALNY","LU2089283258.USD","LU0795875169.SGD","LU2111349929.HKD","LU2089284900.SGD","LU0106261372.USD","BK4581","BK4534","LU1732799900.SGD","LU1732800096.USD","IE00BKVL7J92.USD","LU2271345857.HKD","BK4588","BK4504","LU0912757837.SGD","BK4137","LU0795875086.SGD","LU1720051108.HKD","BK4139","LU2028103732.USD","LU1074936037.SGD","LU1668664300.SGD","HCSG","LU0320765646.SGD","LU1162221912.USD","LU2357305700.SGD","LU0971096721.USD","LU0106831901.USD"],"gpt_icon":1},{"id":"2500033125","title":"Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=2500033125","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500033125?lang=en_us&edition=fundamental","pubTime":"2025-01-04 02:08","pubTimestamp":1735927682,"startTime":"0","endTime":"0","summary":"William Blair has initiated coverage on Denali Therapeutics Inc , a company focused on developing drugs for neurodegenerative diseases.The analyst highlights that Denali is developing a specialized transport vehicle  platform to enhance the delivery of treatments across the blood-brain barrier.It stands out from competitors with its promising potential for top-tier performance and scalability across different therapies and conditions.The company’s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights.The company has reached an agreement with the FDA on the requirements for accelerated approval and plans to submit a biologics license application in early 2025.Insights gained from tividenofusp alfa may also simplify the development and approval process for future treatments targeting other lysosomal storage diseases, such as DNL126 for Sanfilippo syndrome type A.Most recently, Denali Therapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z9P08.USD","LU1074936037.SGD","LU0267386448.USD","BK4548","NVIW.SI","LU1162221912.USD","LU1668664300.SGD","SQQQ","LU0314104364.USD","LU0912757837.SGD","MNQmain","LU0106831901.USD","ALNY","TQQQ","LENZ","LU1989772840.SGD","RNA","BK4505","LU2347655156.SGD","BK4516","LU2023251221.USD","IONS","IE00BZ1G4Q59.USD","TV","BK4581","USJW.SI","PSQ","BK4504","NQmain","TSYW.SI","LU2271345857.HKD",".IXIC","LU0234570918.USD","BK4139","BIIB","LU0158827781.USD","LU0320765646.SGD","LU1720051017.SGD","QID","USAW.SI","LU0109394709.USD","QLD","LU0320765992.SGD","DNLI","RARE","BK4127","LU1363072403.SGD","LU1720051108.HKD","LU0225283273.USD"],"gpt_icon":1},{"id":"2494895425","title":"Exploring High Growth Tech Stocks in the US December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2494895425","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494895425?lang=en_us&edition=fundamental","pubTime":"2024-12-27 02:06","pubTimestamp":1735236399,"startTime":"0","endTime":"0","summary":"The United States market has recently experienced a 2.8% increase over the past week and a substantial 24% climb over the last year, with earnings expected to grow by 15% per annum in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to leverage these favorable market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 238 stocks from our US High Growth Tech and AI Stocks screener.We're going to check out a few of the best picks from our screener tool.Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics utilizing ribonucleic acid interference technology, with a market capitalization of $31.37 billion.Operations: Alnylam Pharmaceuticals focuses on the discovery, development, and commercialization of RNAi-based thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-180639160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SRPT","BK4585","BK4148","LU2211815571.USD","BK4157","LU1861220033.SGD","LU2290526834.HKD","LU2360107168.USD","LU1861215975.USD","BK4588","ALNY","COHR"],"gpt_icon":1},{"id":"2494588022","title":"Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2494588022","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494588022?lang=en_us&edition=fundamental","pubTime":"2024-12-25 22:40","pubTimestamp":1735137611,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alnylam Pharmaceuticals  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Alnylam Pharmaceuticals is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Alnylam Pharmaceuticals is currently sporting a Zacks Rank of #2 .In argenex SE's case, t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-stock-outpacing-144011444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","ARGX","LU0889565916.HKD","LU0320765992.SGD","BK4505","LU0109394709.USD","BK4585","BK4548","ALNY"],"gpt_icon":0},{"id":"2493761282","title":"Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493761282","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493761282?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:09","pubTimestamp":1734966547,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024.In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.  stands against the other biotech stocks.Biotech businesses have been further challenged by volatile market conditions, which have led several of them to reduce programs and lay off huge numbers of employees to save money. Although recent rate cuts may assist in resurrecting scientific initiatives, analysts like Jared Holz point out that it is still challenging to forecast their consequences. Holz also points out that the performance of biotech companies is increasingly matching that of small-cap stocks, indicating a change in market dynamics. Biotech may increase if small-cap stocks trade well, but stagnation could result from momentum loss. Interest rates and biotech success have a relatively recent relationship that emerged after the pandemic when enterprises with a therape","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0jgqfdrHQzF4OTQucn.1Aw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1994f7078bd8ae513263ce18e1f3af94","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0jgqfdrHQzF4OTQucn.1Aw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1994f7078bd8ae513263ce18e1f3af94"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-best-150907742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","CAGR","BK4588","USAW.SI","BK4159","PSQ","TSYW.SI","NVIW.SI","QID","SQQQ","BK4548","BK4585","TQQQ",".IXIC","ALNY","BK4139","USJW.SI","QLD","NQmain"],"gpt_icon":1},{"id":"2493447752","title":"Alnylam Pharmaceuticals: Givlaari NOW Widely Reimbursed in Canada for Treatment of Acute Hepatic Porphyria in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2493447752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493447752?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:06","pubTimestamp":1734959180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALNY","BK4548","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2492412859","title":"The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam","url":"https://stock-news.laohu8.com/highlight/detail?id=2492412859","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492412859?lang=en_us&edition=fundamental","pubTime":"2024-12-20 18:21","pubTimestamp":1734690060,"startTime":"0","endTime":"0","summary":"Chicago, IL – December 20, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sarepta Therapeutics SRPT, ADMA Biologics ADMA, Exelixis EXEL and Alnylam Pharmaceuticals ALNY.It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sarepta-102100191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","BK4588","BK4548","BK4532","IE00BFTCPJ56.SGD","EXEL","IE0002141913.USD","IE00BJT1NW94.SGD","ALNY","ADMA","BK4585","SRPT","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2492248565","title":"4 Biotech Stocks Most Wall Street Analysts Are Bullish About","url":"https://stock-news.laohu8.com/highlight/detail?id=2492248565","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492248565?lang=en_us&edition=fundamental","pubTime":"2024-12-20 02:24","pubTimestamp":1734632640,"startTime":"0","endTime":"0","summary":"It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.Nonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity will likely accelerate in 2025 with a change in administration and expected deregulation. Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts. While oncology and immunooncology companies have always been acquisition targets, those with obesity drugs in their port","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VCILzt0LKKaSV5FPHCcbXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VCILzt0LKKaSV5FPHCcbXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-biotech-stocks-most-wall-182400070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","SRPT","ALNY","BK4532","IE00B2B36J28.USD","IE0009355771.USD","BK4139","BK4588","BK4548","EXEL","IE00BJT1NW94.SGD","ADMA"],"gpt_icon":0},{"id":"2492192498","title":"Leerink Partners Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492192498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492192498?lang=en_us&edition=fundamental","pubTime":"2024-12-18 13:37","pubTimestamp":1734500237,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Mani Foroohar maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday. The company’s shares closed y...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-hold-rating-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-hold-rating-on-alnylam-pharma-alny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2492641147","title":"What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You","url":"https://stock-news.laohu8.com/highlight/detail?id=2492641147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492641147?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:23","pubTimestamp":1734362608,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) price-to-sales (or \"P/S\") ratio of 15.1x might make it look like a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/what-alnylam-pharmaceuticals-incs-nasdaqalny-ps-is-not-telli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TSYW.SI",".IXIC","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","NVIW.SI","SQQQ","QID","USJW.SI","BK4585","QLD","PSQ","MNQmain","BK4548","BK4588","BK4139","USAW.SI","IE00B64PRP62.GBP","IE00BKPKM429.USD","ALNY","NDAQ","TQQQ","BK4112","NQmain","LU2210150020.SGD"],"gpt_icon":1},{"id":"2490862493","title":"CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490862493","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490862493?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:05","pubTimestamp":1733929500,"startTime":"0","endTime":"0","summary":"Cardiff OncologyCRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead investigational candidate, onvansertib , in combination with standard-of-care  chemotherapy to treat first-line RAS-mutated metastatic colorectal cancer  patients. The stock rallied 54.9% on Tuesday following the encouraging news. The primary endpoint of the study was objective response rate , and the secondary endpoints included progression-free survival , duration of response and safety.Per the data from the phase II CRDF-004 study, treatment with the 30 mg dose of onvansertib, a PLK1 inhibitor, demonstrated an ORR of 64%, almost double the 33% ORR observed in the control arm . The 30 mg dose arm also demonstrated a higher ORR compared with the 50% ORR observed in the 20 mg dose arm. Overall, patients treated with onvansertib demonstrated an ORR of 57%.The company also shared spider plots in the press release which show that patients receiving the 30mg dose of onvanser","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crdf-stock-soars-robust-efficacy-150500661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4599","LU0985481810.HKD","IE00B3T34201.USD","IE00B19Z3B42.SGD","BK4533","IE0002270589.USD","IE00B7SZLL34.SGD","BK4578","LU0109394709.USD","IE00BKVL7J92.USD","IE00BLSP4239.USD","LU1066053197.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0234570918.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","PFS","LU0234572021.USD","IE000M9KFDE8.USD","LU1023059063.AUD","LU1057294990.SGD","LU0225284248.USD","LU0321505868.SGD","SG9999011175.SGD","LU0306806265.USD","LU1585245621.USD","SOC","BK4588","BK4581","SG9999001176.SGD","BK4550","GILD","IE00BBT3K403.USD","ALNY","LU0225771236.USD","SG9999002232.USD","BK4534","BK4195","LU2468319806.SGD","BK4213","SG9999002224.SGD","LU1839511570.USD","SGXZ57979304.SGD","CRDF","PFE","LU0306807586.USD","LU0058720904.USD","LU1430594728.SGD","BK4568"],"gpt_icon":1},{"id":"2490862467","title":"QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490862467","media":"Zacks","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490862467?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:02","pubTimestamp":1733929320,"startTime":"0","endTime":"0","summary":"uniQure N.V.QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, a one-time administered investigational gene therapy, which is being developed to treat Huntington’s disease.Huntington's disease is a genetic disorder that causes the progressive breakdown of nerve cells in the brain, which leads to a decline in cognitive and physical abilities, often resulting in movement, thinking and psychiatric problems. uniQure enjoys the FDA’s Regenerative Medicine Advanced Therapy  designationfor AMT-130 to treat Huntington’s disease.uniQure is simultaneously conducting two phase I/II studies of AMT-130, with 26 participants in the United States and 13 in the EU/UK to treat Huntington's disease. Among these, a total of 29 patients received either a low dose  or a high dose  of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/woEWcNDZGH_3gLX_.sdY1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/woEWcNDZGH_3gLX_.sdY1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qure-soars-fda-alignment-speedy-150200885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","SG9999011175.SGD","BK4588","LU1571399168.USD","LU0225284248.USD","LU2087621335.USD","IE000M9KFDE8.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1023059063.AUD","LU0109394709.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU0058720904.USD","SG9999002232.USD","LU0306807586.USD","LU1066053197.SGD","ALNY","LU1430594728.SGD","QURE","SG9999002224.SGD","PFE","BK4568","IE0002270589.USD","LU1057294990.SGD","SG9999001176.SGD","SG9999003800.SGD","LU0306806265.USD","IE00BBT3K403.USD","LU1839511570.USD","LU0234570918.USD","LU0985481810.HKD","BK4550","SGXZ57979304.SGD","BK4533","LU1894683264.USD","LU0225771236.USD","BK4532","IE00BKVL7J92.USD","IE00B3T34201.USD","BK4599","CSF","LU0321505439.SGD","IE00B19Z3B42.SGD","BK4581","LU0234572021.USD","BK4534","GILD","IE00BZ1G4Q59.USD","LU1585245621.USD"],"gpt_icon":1},{"id":"2490774709","title":"FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2490774709","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490774709?lang=en_us&edition=fundamental","pubTime":"2024-12-10 00:26","pubTimestamp":1733761560,"startTime":"0","endTime":"0","summary":"GSK plcGSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication forNucala in chronic obstructive pulmonary disease  treatment for review.A decision from the regulatory body is expected on May 7, 2025.GSK’s Nucala is a monoclonal antibody with a novel mechanism of action that targets IL-5, a key messenger protein  in type 2 inflammation. Please note that Nucala is already approved in the United States for four IL-5-mediated conditions — severe eosinophilic asthma , chronic rhinosinusitis with nasal polyps in adults, eosinophilic granulomatosis with polyangiitis in adults and hypereosinophilic syndrome in patients aged 12+. Currently, the drug is not approved for COPD worldwide.In the past three months, shares of GSK have plunged 21.6% compared with the industry’s 6.2% decline.The new drug application for Blenrep, in combination with J&J’s Velcade  plus dexamethasone , is supported by interim results of the phase III head-to-head DREAMM-7stu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NHx6klCutBjAlMNJEM7HQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-gsks-filing-expanded-162600414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFE","IE00BZ1G4Q59.USD","LU0225284248.USD","BK4548","LU0306806265.USD","LU0868494617.USD","LU1057294990.SGD","LU1066051498.USD","LU1894683348.USD","LU1839511570.USD","SG9999001176.USD","BK4581","BK4534","IE00BLSP4239.USD","BK4566","IE00BBT3K403.USD","LU0234570918.USD","LU0234572021.USD","LU0320765992.SGD","LU1585245621.USD","LU1894683264.USD","SG9999001176.SGD","SG9999003800.SGD","IE00BKVL7J92.USD","LU0306807586.USD","GSK.UK","IE00B7SZLL34.SGD","SG9999002224.SGD","SG9999013999.USD","LU0109394709.USD","GILD","LU1066053197.SGD","BK4007","BK4592","BK4599","LU0058720904.USD","BK4585","IE00B3T34201.USD","LU0122379950.USD","BK4533","ALNY","LU0170899867.USD","GSK","BK4532","LU1883839398.USD","IE00BSNM7G36.USD","LU0456855351.SGD","BK4568","SG9999002232.USD","LU1829250122.USD"],"gpt_icon":1},{"id":"2489615258","title":"TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489615258","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489615258?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:34","pubTimestamp":1733495640,"startTime":"0","endTime":"0","summary":"Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical TARA-002 for treating non-muscle invasive bladder cancer .TARA-002 is Protara’s investigational cell therapy, which is currently in development for treating NMIBC and lymphatic malformations . The candidate enjoys the FDA’s Rare Pediatric Disease designation for treating these indications in the United States.NMIBC patients treated with TARA-002 achieved a complete response  rate of 72% at six months and 70% at any time across BCG exposures with 100% of patients maintaining a CR from three months to six months. Protara also reported that two out of three treated patients maintained a CR at nine months.In the past three months, shares of TARA have skyrocketed 227.2% against the industry’s 7.3% decline.Apart from TARA-002, Protara’s clinical pipeline comprises an investigational IV phosphol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2087621335.USD","SG9999003800.SGD","BK4599","CR","BCG","BK4532","LU0122379950.USD","LU0234570918.USD","SG9999002224.SGD","GILD","LU0321505439.SGD","BK4566","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00BLSP4452.SGD","LU1894683348.USD","IE00B19Z3581.USD","BK4534","PFE","BK4161","SGXZ57979304.SGD","LU1839511570.USD","LU0058720904.USD","LU1066051498.USD","LU1057294990.SGD","BK4139","BK4550","IE00BKVL7J92.USD","BK4007","LU0225771236.USD","LU0306806265.USD","LU0985481810.HKD","IE00B3T34201.USD","LU1883839398.USD","LU0170899867.USD","LU0306807586.USD","IE00B19Z3B42.SGD","LU0868494617.USD","ALNY","SG9999002232.USD","LU0234572021.USD","LU2468319806.SGD","LU0321505868.SGD","LU0889565916.HKD","BK4548","TARA","BK4585","SG9999013999.USD","LU0320765992.SGD"],"gpt_icon":1},{"id":"2489816542","title":"Alnylam Pharma (ALNY) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2489816542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489816542?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:18","pubTimestamp":1733487523,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4548","BK4588","ALNY"],"gpt_icon":0},{"id":"2489148677","title":"What Makes Alnylam (ALNY) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2489148677","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489148677?lang=en_us&edition=fundamental","pubTime":"2024-12-05 01:00","pubTimestamp":1733331611,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Alnylam basically reflects positivity about its earnings outlook that could translate into buying pressure","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XFzKRSTb2_xUaLSOCP9.Bg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XFzKRSTb2_xUaLSOCP9.Bg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-alnylam-alny-buy-stock-170011718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","ALNY","BK4548","BK4139"],"gpt_icon":0},{"id":"2489711902","title":"Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489711902","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489711902?lang=en_us&edition=fundamental","pubTime":"2024-12-04 22:40","pubTimestamp":1733323210,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Sensus Healthcare, Inc.  one of those stocks right now?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Sensus Healthcare, Inc. is one of 1022 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #2 .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensus-healthcare-srts-outperforming-other-144010482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALNY","SRTS"],"gpt_icon":0},{"id":"2488894469","title":"TransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2488894469","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488894469?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:49","pubTimestamp":1733176184,"startTime":"0","endTime":"0","summary":"TransMedics  said Monday it named Gerardo Hernandez as chief financial officer.Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals , TransMedics said.Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.Gordon will then become a non-employee senior advisor to TransMedics focusing on national transplant stakeholder engagement until March 31, 2026, the company said.TransMedics also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.Analysts polled by Factset expect $431.9 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","LU2324357040.USD","TMDX","BK4082","BK4139","BK4585","ALNY","BK4588","LU2065731478.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.1366},{"period":"6month","weight":-0.0766},{"period":"1year","weight":0.2137},{"period":"ytd","weight":0.0223}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.030883},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019432},{"month":5,"riseRate":0.6,"avgChangeRate":0.035453},{"month":6,"riseRate":0.619048,"avgChangeRate":0.064199},{"month":7,"riseRate":0.666667,"avgChangeRate":0.102356},{"month":8,"riseRate":0.571429,"avgChangeRate":0.032179},{"month":9,"riseRate":0.52381,"avgChangeRate":0.035035},{"month":10,"riseRate":0.380952,"avgChangeRate":-0.044018},{"month":11,"riseRate":0.761905,"avgChangeRate":0.082821},{"month":12,"riseRate":0.47619,"avgChangeRate":0.012209}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction